BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21514148)

  • 1. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
    Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
    Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
    Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
    Chen LL; Ye F; Lü WG; Yu Y; Chen HZ; Xie X
    J Obstet Gynaecol Res; 2009 Apr; 35(2):212-8. PubMed ID: 19335794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
    Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
    Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
    da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor.
    Orengo AM; Fabbi M; Miglietta L; Andreani C; Bruzzone M; Puppo A; Cristoforoni P; Centurioni MG; Gualco M; Salvi S; Boccardo S; Truini M; Piazza T; Canevari S; Mezzanzanica D; Ferrini S
    Int J Cancer; 2011 Sep; 129(5):1116-25. PubMed ID: 21710494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor.
    Yigit R; Massuger LF; Zusterzeel PL; Pots J; Figdor CG; Torensma R
    Int J Gynecol Cancer; 2011 Oct; 21(7):1241-7. PubMed ID: 21946293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
    Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma immune analytes in patients with epithelial ovarian cancer.
    Block MS; Maurer MJ; Goergen K; Kalli KR; Erskine CL; Behrens MD; Oberg AL; Knutson KL
    Cytokine; 2015 May; 73(1):108-13. PubMed ID: 25743245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines in peritoneal fluid of ovarian neoplasms.
    de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
    J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Zhu Q; Wu X; Wu Y; Wang X
    Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
    BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer.
    Bednarska K; Klink M; Wilczyński JR; Szyłło K; Malinowski A; Sułowska Z; Nowak M
    Immunobiology; 2016 Feb; 221(2):323-32. PubMed ID: 26563750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
    Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
    Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.